Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIUNASDAQ:AVBPNASDAQ:IMNMNASDAQ:RCKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$1.70+2.7%$1.71$1.43▼$4.98$165.68M1.62170,960 shs147,642 shsAVBPArriVent BioPharma$20.63+0.8%$19.16$15.47▼$36.37$705.81M1.47180,915 shs336,382 shsIMNMImmunome$8.46+6.8%$7.60$5.15▼$16.81$736.12M2917,483 shs803,042 shsRCKTRocket Pharmaceuticals$6.56-0.5%$6.81$4.55▼$26.98$700.52M1.021.51 million shs2.20 million shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-5.71%+7.84%+11.49%-37.97%-50.60%AVBPArriVent BioPharma-1.87%+9.17%+4.76%-25.26%+2.61%IMNMImmunome-7.48%-0.63%-1.00%-21.66%-41.98%RCKTRocket Pharmaceuticals-3.80%+8.93%-8.09%-39.37%-70.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune2.5832 of 5 stars3.53.00.00.02.30.81.3AVBPArriVent BioPharma1.0187 of 5 stars3.60.00.00.02.00.00.0IMNMImmunome2.638 of 5 stars4.50.00.00.03.42.50.0RCKTRocket Pharmaceuticals4.9077 of 5 stars4.53.00.04.73.95.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$10.00489.97% UpsideAVBPArriVent BioPharma 3.14Buy$39.2990.43% UpsideIMNMImmunome 3.00Buy$23.33175.81% UpsideRCKTRocket Pharmaceuticals 2.92Moderate Buy$37.73475.11% UpsideCurrent Analyst Ratings BreakdownLatest ACIU, IMNM, RCKT, and AVBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025AVBPArriVent BioPharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.005/16/2025RCKTRocket PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $30.005/16/2025RCKTRocket PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$32.00 ➝ $32.005/16/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $46.005/14/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/13/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $21.005/12/2025RCKTRocket PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $51.005/12/2025RCKTRocket PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $34.005/9/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$54.00 ➝ $45.005/9/2025RCKTRocket PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $44.005/9/2025RCKTRocket PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.00(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$28.30M6.01N/AN/A$2.12 per share0.80AVBPArriVent BioPharmaN/AN/AN/AN/A($4.79) per shareN/AIMNMImmunome$10.94M67.30N/AN/A$2.77 per share3.05RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$60.41M-$0.58N/AN/AN/AN/A-28.26%-18.98%8/5/2025 (Estimated)AVBPArriVent BioPharma-$69.33M-$3.77N/AN/AN/AN/A-43.89%-29.67%N/AIMNMImmunome-$106.81M-$3.18N/AN/AN/A-3,014.59%-48.63%-41.62%N/ARCKTRocket Pharmaceuticals-$245.60M-$2.63N/AN/AN/AN/A-62.62%-54.17%8/4/2025 (Estimated)Latest ACIU, IMNM, RCKT, and AVBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025RCKTRocket Pharmaceuticals-$0.58-$0.56+$0.02N/AN/AN/A5/12/2025Q1 2025AVBPArriVent BioPharma-$0.66-$1.90-$1.24-$1.90N/AN/A5/12/2025Q1 2025IMNMImmunome-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million5/5/2025Q1 2025RCKTRocket Pharmaceuticals-$0.59-$0.56+$0.03-$0.56$0.80 millionN/A4/30/2025Q1 2025ACIUAC Immune-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million3/19/2025Q4 2024IMNMImmunome-$0.68-$0.84-$0.16-$1.28$3.07 million$2.74 million3/3/2025Q4 2024AVBPArriVent BioPharma-$0.78-$0.60+$0.18-$0.61N/AN/A3/3/2025Q4 2024RCKTRocket Pharmaceuticals-$0.68-$0.62+$0.06-$0.62$0.03 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AAVBPArriVent BioPharmaN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.861.86AVBPArriVent BioPharmaN/A19.2819.28IMNMImmunomeN/A6.176.17RCKTRocket Pharmaceuticals0.066.056.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%AVBPArriVent BioPharma9.48%IMNMImmunome44.58%RCKTRocket Pharmaceuticals98.39%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%AVBPArriVent BioPharmaN/AIMNMImmunome8.60%RCKTRocket Pharmaceuticals24.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million94.39 millionOptionableAVBPArriVent BioPharma4034.21 millionN/AN/AIMNMImmunome4087.01 million72.92 millionOptionableRCKTRocket Pharmaceuticals240106.79 million65.18 millionOptionableACIU, IMNM, RCKT, and AVBP HeadlinesRecent News About These CompaniesToronto Dominion Bank Purchases Shares of 1,100,000 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)May 22 at 5:05 AM | marketbeat.com271,659 Shares in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Purchased by Soleus Capital Management L.P.May 21 at 8:13 AM | marketbeat.comNorthern Trust Corp Has $8.34 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)May 21 at 3:12 AM | marketbeat.comTema Etfs LLC Invests $1.14 Million in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)May 20 at 6:16 AM | marketbeat.comPoint72 Asset Management L.P. Purchases 1,521,727 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)May 20 at 5:30 AM | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Holdings Raised by BNP Paribas Financial MarketsMay 20 at 3:47 AM | marketbeat.comSuvretta Capital Management LLC Invests $32.27 Million in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)May 19 at 7:38 AM | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Earns Outperform Rating from WedbushMay 19 at 3:43 AM | americanbankingnews.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Sphera Funds Management LTD.May 18, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Given New $30.00 Price Target at Cantor FitzgeraldMay 18, 2025 | americanbankingnews.comChardan Capital Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) StockMay 18, 2025 | americanbankingnews.comProsight Management LP Buys 929,337 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)May 17, 2025 | marketbeat.comMPM Bioimpact LLC Decreases Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)May 16, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Estimate for RCKT EarningsMay 16, 2025 | marketbeat.comLMR Partners LLP Takes $943,000 Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)May 16, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 2,106,699 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)May 16, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 7.5% After Analyst DowngradeMay 15, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $51.00 at ScotiabankMay 14, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Given New $34.00 Price Target at Canaccord Genuity GroupMay 14, 2025 | marketbeat.comScotiabank Has Lowered Expectations for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock PriceMay 14, 2025 | americanbankingnews.comCanaccord Genuity Group Has Lowered Expectations for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock PriceMay 14, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACIU, IMNM, RCKT, and AVBP Company DescriptionsAC Immune NASDAQ:ACIU$1.70 +0.05 (+2.73%) Closing price 04:00 PM EasternExtended Trading$1.70 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.ArriVent BioPharma NASDAQ:AVBP$20.63 +0.16 (+0.78%) Closing price 04:00 PM EasternExtended Trading$20.63 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Immunome NASDAQ:IMNM$8.46 +0.54 (+6.82%) Closing price 04:00 PM EasternExtended Trading$8.40 -0.06 (-0.71%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Rocket Pharmaceuticals NASDAQ:RCKT$6.56 -0.03 (-0.46%) Closing price 04:00 PM EasternExtended Trading$6.70 +0.14 (+2.13%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Cathie Wood Just Bought a New Stake in Taiwan Semiconductor Stock Super Micro Computer Stock Clears New Path Higher on Saudi Orders Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith? Why Carnival Could Be the Ultimate Non-Tech Growth Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
